AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Ovoca Bio Plc

Regulatory Filings Nov 13, 2025

1970_rns_2025-11-13_10efe85f-5a25-42d3-92b0-4dadabac2655.html

Regulatory Filings

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 3275H

Ovoca Bio PLC

13 November 2025

Ovoca Bio PLC

13 November 2025

Ovoca Bio plc

("Ovoca" or the "Company")

Change of Broker

Dublin, Ireland, 13 November 2025 - Ovoca Bio Plc announces, in anticipation of completion of the acquisition of Tadeen International Limited as originally announced on 7 May 2025, the appointment of CMC Markets UK Plc, trading as CMC CapX, as broker to the Company with immediate effect. Beaumont Cornish Limited will continue to act as the Company's Nominated Adviser.

End

For further information:

Ovoca Bio plc

Tim McCutcheon (Chief Executive Officer)

Tel +353 1 661 9819

[email protected]

Beaumont Cornish Limited (Nominated Adviser)

James Biddle / Roland Cornish

Tel: +44 (0) 207 628 3396

CMC Markets UK Plc (Broker)

Douglas Crippen

Tel: +44 (0) 20 3003 8632

Nominated Adviser Statement

Beaumont Cornish Limited ("Beaumont Cornish"), is the Company's Nominated Adviser and is authorised and regulated in the United Kingdom by the Financial Conduct Authority. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other person for providing the protections afforded to customers of Beaumont Cornish nor for advising them in relation to the transaction and arrangements described in the announcement or any matter referred to in it.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPEAEFAFDESFAA

Talk to a Data Expert

Have a question? We'll get back to you promptly.